Sade zarif şık aynı zamanda çok abiye durmayan bi elbise yok mu şu piyasada scil üretime geçilmeli

ben bu bölümü atlatamadım nerede o 25 edit scil ihtiyacım var

2) sula leanaim ar aghaidh leis na cinn eile. Chomh maith leis sin, tá feabhas mór tagtha ar mo staid airgeadais, mar sin is féidir íocaíocht a phlé agus a chomh-aontú, níl aon cheist ag baint le hairgead. Dhéanfainn an obair seo mé féin, dá mbeadh an scil agam í a dhéanamh.

Scil gleoite ag Eamonn O Sullivan chun an cúilín a fháíl O Sullivan has been on fire today 🔥🔥 51 Nóim @LimerickCLG 0-14 (14) @Galway_GAA 1-21 (24) @GAA_BEO #GAABeo

Bu adam scil tedavi görmeli ki zaten depresyon tedavisi gördüğü biliniyorbu u kala almayın zatenkuçu olarak biliniyor.

@abakingurlek @adalet_bakanlik adli scil ve arşiv ile ilgili çalışma olmadığı sürece tahliye olanların hayata tutunması zor.Bir defaya mahsus 2 yıl altı cezalarda ve basit suçlarda sicil ve arşiv temizlenmeli !

Yaparken aklın neredeydi scil dosyana işlensin de gör günü #yılser #halef

arkadaslar pembe mi kirmizi mi acilll cok scil asiri scil yazin

Thank you to Alison and Jo from the Bradford SCIL team for this week’s staff training on supporting SEMH needs in the classroom. Plenty of useful ideas and strategies to take forward into practice. #SEMH #CPD @CATAcademyTrust @SENDBradford #SCIL #Inclusion

Knk nasıl yaptın scil

SUDAN ZEHIRLENIR MIYIM SCIL BAKIN COK ONEMLI

Sumitomo Chemicals - Q4 and FY 26 results and concall highlights - Q4 outcomes - Revenues - 684 cr, up 1 pc Gross margins @ 42.3 vs 40 pc EBITDA - 134 cr, up 12 pc ( margins @ 19.6 vs 17.6 pc ) PAT - 112 vs 100 cr, up 12 pc FY 26 outcomes - Revenues - 3238 cr, up 3 pc Gross margins @ 42 vs 41 pc EBITDA - 671 cr, up 6 pc ( margins @ 20.7 vs 20.1 pc ) PAT - 543 cr, up 7 pc Exports De-Grew 7 pc in Q4 and by 1 pc in FY 26. African business however did exceptionally well, going by 26 pc and 30 pc in Q4 and FY 26 respectively Herbicides grew strongly in Q4 and FY 26, growing by 87 pc and 19 pc respectively. Metal Phosides grew by 16 pc and 11 pc in Q4 and FY 26 Product-led execution remained a key focus area during FY26. Newly launched products including Lentigo ( next generation Paddy herbicide ), Excalia Max ( next generation Fungicide for Paddy crop ), Powerpull ( broad spectrum insecticide ), Advika ( broad spectrum insecticide ), Envoy ( broad spectrum insecticide ) and Oslava ( received encouraging market response. Registration of Topgrain ( BioStimulant ) was also completed during the year - strengthening the future product pipeline FY 26 domestic:export sales @ 79:21 Breakup of Branded:Bulk sales in domestic mkt @ 81:77 Breakup of Branded:Bulk sales in export mkt @ 40:60 Breakup of company level patented:generic mix of sales @ 29:71 Company makes 14 AIs in house, has 5 manufacturing facilities ( 3 AIs 2 formulations ), has a field force @ 1500 employees Key export destinations include - LatAm, Japan, Africa, Asia ( ex-India ) Notes from previous concalls - Company continues to work towards strengthening Sumitomo Japan’s supply chains and concentrating them in India for future exports to RoW with India as a key manufacturing base Company is in the process of registering its formulations in various export mkts. Registration of these take time ( 2-3 yrs, depending on country to country ). As these registrations keep maturing, company’s share of formulations in their export business shall improve ( this segment has better margins vs AIs ). At present, most of company’s export sales are AIs and share of Formulations in export sales is far lower Have approved a Greenfield capex @ Dahej - to expand company's manufacturing footprint for local and global supplies. Company is evaluating manufacturing of 7 new products ( AIs ) @ Dahej Greenfield facility. Company has submitted feasibility reports iro these products to its parent in Japan. If all are approved to be made in India ( @ Dahej ), company may incur a capex of aprox 500- 600 cr over next 3 odd years @ Dahej Company’s semiconductor chemicals shall be used in fabrication. Company is monitoring the progress of corporates ( specially TATAs ) setting up fabrication plants in India. Once that happens, company shall begin their Semi Conductor chemicals business Notes from Q4 concall - FY 26 was one of the most challenging years in Indian Agrochemicals industry due persistent and prolonged rains well into Oct 25. PGRs, Biologics solutions were severely impacted. Exports were hit in Mar 26 due war in Iran. Consumption of insecticides was also affected adversely due unseasonal rains Company's share of revenues from Biologics @ aprox 10 pc vs industry avg of sub 5 pc. Should see accelerated growth in Biologics wef FY 27 Lentigo and Excallia Max are both patented molecules ( launched LY ) - both did exceedingly well LY Products launched in last 3 yrs now contribute to 8 pc of their revenues Will introduce another 2-3 patented products in India over next 1-2 yrs Risks for FY 27 - constrained availability of Fertilizers due Iran war, El-Nino induced below normal rainfall, escalating RM prices At present, aprox 56 pc of Indian net sown area is covered by assured irrigation facilities - making Indian agriculture relatively insulated by vagaries of weather Have been passing on the RM prices in a calibrated manner. Demand continues to hold up in Q1 FY 27 Cash on books @ 2133 cr India has been upgraded to same level as North America, Japan, LatAm - for testing and early stage introduction of new / patented molecules developed by company's parent ( SCC Japan ). Have received 2 molecules for local trials. Its a very positive development Discussing a new Royalty arrangement with their parent ( previously were not paying any royalty ) - in return for flexibility to SCIL to procure RMs/Technicals locally. At present, such arrangement will be limited to only 2-3 products Insecticides share of company's revenues is the highest @ 41 pc Companys exports and RM imports are roughly equally matched @ aprox $ 70-80 million each - insulating them from currency movements All the meetings with GoI wrt manufacturing and commercialisation of speciality chemicals for Semi Conductor manufacturings are being jointly attended by SCIL and SCC Japan. Should hear some good news in future Custom synthesis revenues are roughly around 120 to 150 cr - company does this for their parent. Should see good growth in this segment in medium term Committed to sustain their margins in FY 27 - despite the challenges in RM prices. Have already taken 3 price hikes post the breakout of war in the Gulf Have deliberately over produced in Q4 - to insulate against supply shocks Expect to launch TopGrain ( BioStimulant ) 1 more speciality product in India in FY 27 Phase 1 of Dahej capex should cost them aprox 150 cr - to be completed over next 18 odd months. Expect a series of more announcements going forward Company reduced its animal nutrition trading and distribution business in FY 26. Adjusted for that, their core agrochemicals business grew by 6 pc in FY 27 PGRs were affected in FY 26 due excessive rains that led to sharp decline in Grapes output. In addition, there were additional approvals as mandated by GoI for sale of PGRs in India. Company has completed most of them. FY 27 should be a good year for their PGR business Similarly, fungicide and insecticide sales were badly affected due excessive rains The cash on books shall be used for organic capex in both agrochemicals and semiconductor chemicals related expansion projects In general, farmers are more concerned about electricity, fertiliser prices vs agrochemicals ( as agrochemicals r generally used at later stages when the farmer has a good visibility on the crop and their cost vs fertilisers r also lower ) Disc: holding, biased, not SEBI registered, not a buy/sell recommendation, posted only for educational purposes

Hangi MARKET SCIL

𝗦𝘂𝗺𝗶𝘁𝗼𝗺𝗼 𝗖𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗜𝗻𝗱𝗶𝗮 𝗟𝘁𝗱. - 𝗙𝗬26 𝗘𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗖𝗮𝗹𝗹 𝗦𝘂𝗺𝗺𝗮𝗿𝘆 📈: Sumitomo Chemical India Limited (SCIL) achieved its highest-ever profitability in FY26, navigating a challenging agrochemical industry landscape. Despite adverse weather, regulatory constraints, and global trade uncertainties, the company demonstrated remarkable stability and financial performance. 🌦️ 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - 𝗣𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆: Achieved record profitability in absolute terms & margin terms. ▸ Profit After Tax (PAT) grew over 7% YoY to ₹543 Cr. 💰 ▸ Profit Before Tax (PBT) before exceptional items grew over 9% YoY. ▸ Gross Profit Margin: 42% ▸ EBITDA Margin: 20.7% ▸ Net Profit Margin: 16.8% - 𝗥𝗲𝘃𝗲𝗻𝘂𝗲: Top-line grew by 3% YoY to ₹3,238 Cr. - 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗜𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆: Maintained complete pricing integrity with negligible returns of goods. - 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗖𝗮𝗽𝗶𝘁𝗮𝗹: Net working capital stood at 103 days (vs. 89 days YoY), reflecting deliberate inventory buildup for kharif season & tighter credit terms. - 𝗕𝗮𝗹𝗮𝗻𝗰𝗲 𝗦𝗵𝗲𝗲𝘁: Remains debt-free with cash & cash equivalents of approx. ₹2,113 Cr. - 𝗥𝗲𝘁𝘂𝗿𝗻 𝗼𝗻 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗘𝗺𝗽𝗹𝗼𝘆𝗲𝗱 (𝗥𝗢𝗖𝗘): Improved to 31% from 29% YoY. 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 & 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: - 𝗔𝗴𝗿𝗼𝗰𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆: FY26 was one of the most challenging years due to excess rainfall impacting kharif season & subdued rabi recovery. Biostimulant & PGR categories faced regulatory constraints. 🌧️ - 𝗗𝗼𝗺𝗲𝘀𝘁𝗶𝗰 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀: Grew 4% YoY, with branded formulation share improving to 81% (from 79% in FY25), indicating a shift towards higher-margin revenue. 💪 - 𝗘𝘅𝗽𝗼𝗿𝘁𝘀: Declined 7% in Q4 & 1% for the full year due to shipment differences & softer demand. - 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗖𝗮𝘁𝗲𝗴𝗼𝗿𝗶𝗲𝘀: ▸ Herbicides: Strong growth of 19% YoY, driven by soybean herbicide flumioxazin, new rice herbicide Lentigo, & flagship brand Mera 71 (glyphosate). ▸ Metal Phosphates: Grew 16% in Q4 & 11% for the full year. ▸ Insecticides: Remained broadly resilient. ▸ Biostimulants: Impacted by regulatory constraints but sales commenced under new approvals; new product 'Top Grain' to be launched soon. Biologicals contribute 8-10% of revenue. - 𝗡𝗲𝘄 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀: 7 products launched in FY26, with proprietary technologies Lentigo & Excalia Max exceeding targets. Products launched in last 3 years contribute ~8% of domestic revenue. - 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗢𝘂𝘁𝗿𝗲𝗮𝗰𝗵: Expanded digital outreach to farmers, increasing localized landing pages by 20% & digital campaigns by 35%. - 𝗗𝗲𝗺𝗮𝗻𝗱 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻: Focused on farmer connect & ground-level demand pull through senior management field engagement. 👨‍🌾 𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸 & 𝗚𝘂𝗶𝗱𝗮𝗻𝗰𝗲 (𝗙𝗬27): - 𝗢𝗽𝘁𝗶𝗺𝗶𝘀𝗺: Cautiously optimistic for FY27, with resilient Indian agriculture sector & increased MSPs. - 𝗥𝗶𝘀𝗸𝘀: ▸ Timely & adequate fertilizer supply. ▸ Monsoon uncertainty (IMD forecast: 92% of LPA; El Nino probability). ▸ Geopolitical developments leading to cost headwinds (depreciating rupee, raw materials, transportation). - 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: Gradual & systematic price pass-through of cost increases, calibrated product-by-product. Production running at full capacity. 𝗞𝗲𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁𝘀: - 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗧𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻: Proposed changes effective Sept '26. Mr. Chetan Shah to become Non-Executive Director & potential Chairman. Dr. Suresh Ramachandran to be appointed MD. Mr. Sushil Marfatia to retire from Executive Director role. 🤝 - 𝗦𝗲𝗺𝗶𝗰𝗼𝗻𝗱𝘂𝗰𝘁𝗼𝗿 𝗖𝗵𝗲𝗺𝗶𝗰𝗮𝗹𝘀: Parent company planning commercialization of high-purity semiconductor chemicals in India; SCIL is closely involved & looking forward to project fructification. 💡 - 𝗔𝗻𝗶𝗺𝗮𝗹 𝗡𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻: Restarting distribution of animal nutrition products in India due to global supply chain challenges. Expected to add revenue but profitability impact is limited (~4-5%). - 𝗥𝗼𝘆𝗮𝗹𝘁𝘆 𝗔𝗿𝗿𝗮𝗻𝗴𝗲𝗺𝗲𝗻𝘁: Discussing a new royalty arrangement for 2-3 selected products where SCIL can procure technicals from outside, while using parent's know-how, trademarks & brand. Expected to be immaterial. 📄 - 𝗖𝗮𝗽𝗲𝘅: Commitment to invest in manufacturing infrastructure. Advanced stages for feasibility of additional capex projects. Expecting a sustained pipeline of capex over the next decade. INR150 Cr capex at Dahej site progressing well. 🏗️ - 𝗜𝗻𝗱𝗶𝗮 𝗮𝘀 𝗛𝘂𝗯: India elevated for early-stage testing & introduction of new molecules from SCC global pipeline. SCIL to be involved in manufacturing for global requirements, funded by accumulated cash in India. 🌏 - 𝗖𝘂𝘀𝘁𝗼𝗺 𝗦𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 (𝗖𝗥𝗔𝗠𝗦/𝗖𝗦𝗠): Revenue in the range of ₹100-150 Cr, with expected growth from next financial year onwards. 𝗤&𝗔 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: - 𝗘𝘅𝗽𝗼𝗿𝘁 𝗠𝗮𝗿𝗴𝗶𝗻𝘀: Price realization improved due to geopolitical tensions, but cost escalations largely offset margin benefits. Volume upside depends on logistics & customer affordability. - 𝗠𝗮𝗿𝗴𝗶𝗻 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆: Company confident in sustaining margins through product mix, flexibility, & calibrated pricing actions. - 𝗜𝗻𝘃𝗲𝗻𝘁𝗼𝗿𝘆: Deliberately increased inventory levels for critical raw materials & packaging to mitigate supply chain volatility & increased lead times. - 𝗡𝗲𝘄 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲: 'TopGrain' biostimulant expected in upcoming kharif. Further product registrations & launches anticipated. - 𝗥𝗮𝘄 𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝗣𝗿𝗼𝗰𝘂𝗿𝗲𝗺𝗲𝗻𝘁: No disruption in procurement; prudently stocked up. Permission from parent for importing technicals for 2-3 selected products for flexibility. - 𝗕𝗮𝗿𝗿𝗶𝘅 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: Regulatory challenges largely resolved; business has restarted. - 𝗣𝗿𝗶𝗰𝗲 𝗛𝗶𝗸𝗲𝘀: Product-specific price hikes taken, varying from 10-25% depending on the product, to pass on cost increases. - 𝗩𝗼𝗹𝘂𝗺𝗲 𝘃𝘀. 𝗣𝗿𝗶𝗰𝗲: Revenue growth in FY26 primarily driven by volume, with stable pricing for the full year. Q4 growth had a component of price increase & potential channel stocking. - 𝗚𝗹𝘆𝗽𝗵𝗼𝘀𝗮𝘁𝗲 𝗣𝗿𝗶𝗰𝗲𝘀: Increased significantly due to raw material cost rise & channel stocking. - 𝗦𝗲𝗺𝗶𝗰𝗼𝗻𝗱𝘂𝗰𝘁𝗼𝗿 𝗖𝗮𝗽𝗲𝘅: SCIL's R&D team is capable & will lead efforts, without requiring capital or manpower from Japan. - 𝗙𝗮𝗿𝗺𝗲𝗿 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰𝘀: Agrochemicals represent a smaller portion of farmer costs; farmers prioritize crop protection at the time of need. 🌾 📊 SUMITOMO CHEMICAL INDIA LTD | 🏷️ Earnings Call Transcript 🌐 Details: wegro.app/ltdQj5 ⚡️Instant stock alerts on WhatsApp - Try FREE 👉 wegro.app/go

Happy Pride!!! feat Ranun and Scil, our OCs!! @vittyfish

cips aliyim mi scil

‘The truth taught us in this promise [scil. John 5:24] is not that if, after believing in Christ, we live in sin and die without repentance, we shall, nevertheless, escape condemnation; but that provision is made, on behalf of believers, that they shall not live in sin;

𝗦𝘂𝗺𝗶𝘁𝗼𝗺𝗼 𝗖𝗵𝗲𝗺𝗶𝗰𝗮𝗹 𝗜𝗻𝗱𝗶𝗮 𝗟𝘁𝗱: 𝗙𝗬26 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 & 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗥𝗲𝘃𝗶𝗲𝘄 📊 : Sumitomo Chemical India Ltd (SCIL) demonstrated resilience in FY26, navigating a challenging agrochemical industry environment characterized by prolonged rainfall, delayed demand recovery, and regulatory hurdles. Despite these headwinds, the company achieved remarkable stability and its highest-ever profitability for the fiscal year. 𝗞𝗲𝘆 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲 𝗠𝗲𝘁𝗿𝗶𝗰𝘀: - 𝗥𝗲𝘃𝗲𝗻𝘂𝗲: ▸ Q4FY26 Revenue: ₹684 Cr (Broadly stable YoY). ▸ FY26 Revenue: ₹3,238 Cr (3% YoY growth), despite lower contribution from the Animal Nutrition business & softer agri-input demand. - 𝗣𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆: ▸ PBT before exceptional items increased 11% YoY in Q4FY26 & 9% YoY in FY26. ▸ PAT increased 12% YoY in Q4FY26 & 7% YoY in FY26, reaching ₹543 Cr for FY26. ▸ Net Profit Margins improved to 16.3% in Q4FY26 & 16.8% in FY26, driven by a favorable product mix & calibrated pricing. - 𝗦𝗲𝗴𝗺𝗲𝗻𝘁 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲: ▸ Domestic business grew 4% YoY in both Q4FY26 & FY26. ▸ Africa exports showed strong momentum, with 30% YoY growth in Q4FY26 & 26% YoY in FY26. ▸ Herbicides saw robust growth of 87% YoY in Q4FY26 & 19% YoY in FY26. ▸ Metal Phosphides grew 11% YoY in FY26. 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 & 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆: - 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝘀: Encouraging market response for newly launched products like Lentigo, Excalia Max, and others. Registration of Topgrain completed. - 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗲: Strong focus on profitability-led growth, receivables management, inventory control, and working capital practices. - 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻: Strategic use of digital marketing & phygital experiences (like 'Live Field Days') to enhance farmer engagement & business growth. - 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴: Operates 5 manufacturing facilities with strategic locations. Announced CAPEX of ~₹160 Cr for new projects at Dahej & Tarapur sites, primarily for supply to the parent company. - 𝗥&𝗗: Possesses 3 DSIR-approved R&D labs focused on synthesis, technical product, and formulation development, holding 25 patents. - 𝗕𝗼𝗮𝗿𝗱 & 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁: Key leadership transitions proposed effective Sept 1, 2026, including a new MD & Chairman. 𝗢𝘂𝘁𝗹𝗼𝗼𝗸: Management remains cautiously optimistic, monitoring weather conditions, potential El-Nino effects, raw material inflation, and geopolitical developments. The focus remains on demand generation, differentiated products, calibrated pricing, and strengthening channel partnerships for sustainable growth in FY27. 🌱 📊 SUMITOMO CHEMICAL INDIA LTD | 🏷️ Investor Presentation 🌐 Details: wegro.app/i0vnLf ⚡️Instant stock alerts on WhatsApp - Try FREE 👉 wegro.app/go